譽燊豐控股(02132.HK)中期純利2861.3萬港元 同比增加44.71%
格隆匯11月26日丨譽燊豐控股(02132.HK)公吿,截至2021年9月30日止6個月中期業績,公司實現收入為4.79億港元,同比增加118.28%;公司擁有人應占期內溢利及全面收入總額2861.3萬港元,同比增加44.71%;每股基及攤薄盈利1.79港仙。
集團將繼續(i)積極關注2019冠狀病毒病的發展及項目進度,並與供應商及分包商進行溝通;(ii)與其客户及項目所有人的其他代表密切溝通最新項目工程計劃及安排;及(iii)與潛在客户積極跟進已提交的投標及報價,並積極迴應任何業務諮詢、招標及報價邀請以維持市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.